Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in diastolic heart failure
NCT00523757Phase 3Completed
- Start
- Aug 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Left Ventricular Hypertrophy at 4 months. Started Aug 2007; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00523757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523757.